To hear about similar clinical trials, please enter your email below
Trial Title:
Quest for Tumour Evolution of Non-small Cell Lung Cancer
NCT ID:
NCT05811169
Condition:
Non-small Cell Lung Cancer
Conditions: Official terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Conditions: Keywords:
Next Generation Sequencing
Study type:
Observational
Overall status:
Active, not recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Genetic
Intervention name:
Next generation sequencing
Description:
Next generation sequencing
Arm group label:
Early or metastatic non-small cell lung cancer
Summary:
To study and comprehend the evolutionary and genomic landscape between primary and
metastatic sites and the dynamics of intratumour and intertumour heterogeneity over time
with reference to the treatment modalities for each Chinese patient with non-small cell
lung cancer.
Detailed description:
The importance of intratumour and intertumour heterogeneity in non-small cell lung cancer
has been extensively interrogated recently. However there is a lack of similar data
associated with treatment and survival outcomes in Chinese population. Unicorn-Quest, a
prospective observational study of Chinese patients with either primary or metastatic
non-small cell lung cancer, aims to identify the evolutionary changes from the primary
tumour, regional nodes and distant metastases of the same patients and among different
patients, through multiregion and longitudinal tumour and nodal collection with
next-generation sequencing. By following non-small cell lung cancer from early stage to
relapse or distant metastasis, identifying the changes of genomic landscape with
correlation with treatment and survival outcomes, this study may help identify unique
cancer trajectories and novel therapeutic targets for non-small cell lung cancer in
Chinese population.
Criteria for eligibility:
Study pop:
Stage I to IVB non-squamous non-small cell lung cancer
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Written Informed consent
- Patients ≥18 years of age, with histologically confirmed non-squamous non-small cell
lung cancer who plan to receive active anti-cancer treatment for their non-small
cell lung cancer.
- Sufficient tissues with a minimum of two tumour or nodal regions are available for
the study based on pre-operative imaging and post-operative pathological findings.
Exclusion Criteria:
- Any other* malignancy diagnosed or relapsed at any time, which is currently being
treated (including by hormonal therapy).
Any other* current malignancy or malignancy diagnosed or relapsed within the past 3
years**.
*Exceptions are: non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ
cervical cancer
**An exception will be made for malignancies diagnosed or relapsed more than 2, but less
than 3, years ago only if a pre-operative biopsy of the lung lesion has confirmed a
diagnosis of NSCLC.
- Psychological condition that would preclude informed consent
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Locations:
Facility:
Name:
Department of Clinical Oncology, Queen Mary Hospital
Address:
City:
Hong Kong
Country:
Hong Kong
Start date:
February 15, 2023
Completion date:
December 31, 2026
Lead sponsor:
Agency:
The University of Hong Kong
Agency class:
Other
Collaborator:
Agency:
Queen Mary Hospital, Hong Kong
Agency class:
Other
Collaborator:
Agency:
Queen Elizabeth Hospital, Hong Kong
Agency class:
Other
Collaborator:
Agency:
Pamela Youde Nethersole Eastern Hospital
Agency class:
Other
Collaborator:
Agency:
Prince of Wales Hospital, Shatin, Hong Kong
Agency class:
Other
Collaborator:
Agency:
Princess Margaret Hospital, Hong Kong
Agency class:
Other
Collaborator:
Agency:
Tuen Mun Hospital
Agency class:
Other
Collaborator:
Agency:
United Christian Hospital
Agency class:
Other
Source:
The University of Hong Kong
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05811169
